Sorry, you need to enable JavaScript to visit this website.

You are here

Recent Pfizer Press Releases

2/9/16 6:57pm EST
Pfizer Commends The FDA Advisory Committee’s Vote To Approve Proposed Biosimilar Infliximab, The First Biosimilar Monoclonal Antibody Reviewed, For All Eligible Indications

Pfizer Inc. commends today’s recommendation by the United States (U.S.) Food and Drug Administration’s (FDA) Arthritis Advisory Committee to approve the investigational biosimilar infliximab (CT-P13) across all eligible indications by a vote of 21 to three. Celltrion's proposed biosimilar infliximab, to which Pfizer holds exclusive U.S.

more...
2/8/16 9:30am EST
Pfizer Names Executive Leadership Team for Combined Organization Upon Close of Proposed Allergan Transaction

Pfizer will continue to manage its commercial operations through two distinct businesses – the innovative products business and the established products business – after the completion of the proposed transaction
 
Pfizer continues to expect to make a decision about a potential separation of the combined company’s innovative and established businesses by no later than the end of 2018

Pfizer Inc. (NYSE: PFE) today announced the executive leadership team for the combined Pfizer and Allergan plc (NYSE: AGN) business following the close of the proposed transaction.

more...
2/2/16 6:45am EST
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2015 RESULTS PROVIDES 2016 FINANCIAL GUIDANCE

 

 

 

Please find Pfizer’s press release and associated financial tables, including reconciliations of certain GAAP reported to non-GAAP adjusted information, at the following hyperlink:
more...
1/8/16 4:13pm EST
Pfizer Expands R&D Equity Investment Strategy to Access Early-Stage Scientific Innovations

Initial Investments in Companies Focused on Conditionally Active Biologics, Immuno-Oncology, Neurodegenerative Technologies and Gene Therapy Provide Access to Pfizer Resources to Help Accelerate Research into Novel Pathways and Technologies

Pfizer Inc. (NYSE:PFE) today announced an expansion of its Research & Development (R&D) investment strategy to include early-stage companies on the leading edge of scientific innovation, providing them with both equity and access to resources for research in promising areas aligned with Pfizer’s core interests.

more...
1/8/16 8:00am EST
Pfizer Enters into Translational Research Collaboration with Adaptive Biotechnologies to Help Advance Novel Immuno-Oncology Solutions

Pfizer Inc. (NYSE: PFE) and Adaptive Biotechnologies Corporation have entered into a translational research collaboration to leverage next generation sequencing of the adaptive immune system to advance Pfizer’s growing immuno-oncology franchise.

more...
1/4/16 8:00am EST
Merck KGaA, Darmstadt, Germany, Pfizer and Syndax Announce Collaboration to Evaluate Combination of Avelumab and Entinostat in Ovarian Cancer

  • Merck KGaA, Darmstadt, Germany, Pfizer and Syndax will collaborate to investigate safety, tolerability and preliminary efficacy of avelumab and entinostat in advanced ovarian cancer

Merck KGaA, Darmstadt, Germany, Pfizer and Syndax Pharmaceuticals, Inc.

more...